Search from website
Search from website
From antibody humanization and reformatting to afucosylated bispecific antibodies – we have developed and produced them all. Our technology and experience gives us an ability to discover antibodies against difficult multi-pass transmembrane proteins.
Icosagen provides antibody discovery and development services, using proprietary technologies.
Our proprietary HybriFree technology is based on B-cell cloning, and is used for efficient discovery of monoclonal antibodies and their immediate production in mammalian cells.
HybriFree makes antibody discovery rapid and flexible, and allows cloning antibodies even from recovered patients’ PBMCs and existing hybridomas.
REMEMBER: ANTIGEN MATTERS! Even the smallest difference between an antigen and the natural target protein will affect the antibody specificity and biological function.
Our HybriFree technology delivers high quality antibodies suitable from IVD purposes, in pre-clinical and clinical in vitro and in vivo studies, to even for developing human biopharmaceutical drugs
We clone antibodies from hybridomas, provided by our customers, and produce them at requested scales.
In addition, we deliver the cDNA sequence encoding the antibody variable heavy (VH) and light (VL) domains.
Humanization of antibodies discovered from non-humanized animals or libraries is a necessity for their use as therapeutics. The challenge is to retain the desired specificity and affinity, while engineering away their immunogenic properties.
Our humanization platform service benefits from a proprietary software developed in collaboration with the University of Tartu.
We routinely humanize variable regions and framework sequences from any species, using any reference sequence as the basis. Key residues important for the VH/VL interface and antibody structure are maintained as much as possible in the humanized variants. Humanized sequences are screened to be free of motifs that are prone to glycosylation, deamidation or other PTMS.